CCL3 and hematologic disorder: Since therapeutic treatment of many hematologic malignancies requires a functional HSPC pool to reestablish hematopoietic homeostasis, it is critical that treatment, including CCL3 inhibition avoids reduction of HSPCs within the bone marrow.